Skip to main content

DNA09-A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

Clinical Trial Grant
Duke Scholars

Awarded By

Immunovant

Start Date

June 30, 2025

End Date

April 7, 2034
 

Awarded By

Immunovant

Start Date

June 30, 2025

End Date

April 7, 2034